Emens, L. A. et al. Challenges and alternatives in most cancers immunotherapy: a Society for Immunotherapy of Most cancers (SITC) strategic imaginative and prescient. J. Immunother. Most cancers 12, e009063 (2024).
Atkins, M., Kunkel, L., Sznol, M. & Rosenberg, S. Excessive-dose recombinant interleukin-2 remedy in sufferers with metastatic melanoma: long-term survival replace. Most cancers J. Sci. Am. 6, 11–14 (2000).
Yang, J. C. et al. Randomized research of high-dose and low-dose interleukin-2 in sufferers with metastatic renal most cancers. J. Clin. Oncol. 21, 3127–3132 (2003).
He, X. & Xu, C. Immune checkpoint signaling and most cancers immunotherapy. Cell Res. 30, 660–669 (2020).
Irvine, D. J., Maus, M. V., Mooney, D. J. & Wong, W. W. The way forward for engineered immune cell therapies. Science 378, 853–858 (2022).
Rosenberg, S. A. & Restifo, N. P. Adoptive cell switch as customized immunotherapy for human most cancers. Science 348, 62–68 (2015).
Awasthi, R., Maier, H. J., Zhang, J. & Lim, S. Kymriah® (tisagenlecleucel)–An summary of the scientific growth journey of the primary accepted CAR-T remedy. Hum. Vaccin. Immunother. 19, 2210046 (2023).
Julve, M., Lythgoe, M. P., Larkin, J. & Furness, A. J. S. Lifileucel: the primary mobile remedy accepted for stable tumours. Traits Most cancers 10, 475–477 (2024).
Monberg, T. J., Borch, T. H., Svane, I. M. & Donia, M. TIL remedy: info and hopes. Clin. Most cancers Res. 29, 3275–3283 (2023).
Liu, Y., Sperling, A. S., Smith, E. L. & Mooney, D. J. Optimizing the manufacturing and antitumour response of CAR T remedy. Nat. Rev. Bioeng. 1, 271–285 (2023).
Matsueda, S., Chen, L., Li, H., Yao, H. & Yu, F. Latest scientific researches and technological growth in TIL remedy. Most cancers Immunol. Immunother. 73, 232 (2024).
Hyun, J., Kim, S. J., Cho, S. D. & Kim, H. W. Mechano-modulation of T cells for most cancers immunotherapy. Biomaterials 297, 122101 (2023).
Wang, F. Y., Qiu, T., Ling, Y., Yang, Y. & Zhou, Y. Bodily and chemical cues on the nano–bio interface for immunomodulation. Angew. Chem. 61, e202209499 (2022).
Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Particular activation and focusing on of cytotoxic lymphocytes by way of chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720–724 (1993).
Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor results and may set up reminiscence in sufferers with superior leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. US Meals and Drug Administration https://www.fda.gov/medication/resources-information-approved-drugs/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute (2024).
Juan, M., Delgado, J., Calvo, G., Trias, E. & Urbano-Ispizua, Á. Is hospital exemption another or a bridge to european medicines company for growing educational chimeric antigen receptor T-cell in Europe? Our expertise with ARI-0001. Hum. Gene Ther. 32, 1004–1007 (2021).
Damodar, S. et al. Early outcomes from a phase-2 research of varnimcabtagene autoleucel (IMN-003A), a first-in-India trade CD19-directed CAR-T cell remedy with fractionated infusions for sufferers with relapsed and/or refractory B cell malignancies (IMAGINE research). Blood 140, 10343–10344 (2022).
Oliver-Caldes, A. et al. Biomarkers of efficacy and security of the educational BCMA-CART ARI0002h for the remedy of refractory a number of myeloma. Clin. Most cancers Res. 30, 2085–2096 (2024).
Nie, T. Talicabtagene autoleucel: first approval. Mol. Diagn. Ther. 28, 495–499 (2024).
Therapeutics publicizes NMPA approval of the supplemental organic license software for Carteyva in grownup sufferers with relapsed or refractory mantle cell lymphoma. JW Therapeutics https://www.jwtherapeutics.com/en/media/press-release/20240827/ (2024).
Wang, Y. et al. Inaticabtagene autoleucel in grownup relapsed or refractory B-cell acute lymphoblastic leukemia. Blood Adv. 9, 836–843 (2025).
Saez-Ibañez, A. R. et al. The altering panorama of most cancers cell therapies: scientific trials and real-world information. Nat. Rev. Drug Discov. 23, 736–737 (2024).
Rosenberg, S. A., Spiess, P. & Lafreniere, R. A brand new method to the adoptive immunotherapy of most cancers with tumor-infiltrating lymphocytes. Science 233, 1318–1321 (1986).
Diorio, C., Teachey, D. T. & Grupp, S. A. Allogeneic chimeric antigen receptor cell therapies for most cancers: progress made and remaining roadblocks. Nat. Rev. Clin. Oncol. 22, 10–27 (2025).
Hopewell, E. L., Cox, C., Pilon-Thomas, S. & Kelley, L. L. Tumor infiltrating lymphocytes streamlining a posh manufacturing course of. Cytotherapy 21, 307–314 (2018).
Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell remedy for stable tumours. Nat. Rev. Clin. Oncol. 20, 49–62 (2022).
Albelda, S. M. CAR T cell remedy for sufferers with stable tumours: key classes to be taught and unlearn. Nat. Rev. Clin. Oncol. 21, 47–66 (2023).
Zhao, Y. et al. Tumor infiltrating lymphocyte (TIL) remedy for stable tumor remedy: progressions and challenges. Cancers 14, 4160 (2022).
Madkour, L. H. in Nanoelectronic Supplies: Fundamentals and Purposes (ed. Madkour, L. H.) 1–47 (Springer, 2019).
Mitchell, M. J. et al. Engineering precision nanoparticles for drug supply. Nat. Rev. Drug Discov. 20, 101–124 (2020).
Joyce, P. et al. A translational framework to DELIVER nanomedicines to the clinic. Nat. Nanotechnol. 19, 1597–1611 (2024).
Anselmo, A. C. & Mitragotri, S. Nanoparticles within the clinic: an replace submit COVID-19 vaccines. Bioeng. Transl. Med. 6, e10246 (2021).
Hou, F., Guo, Z., Ho, M. T., Hui, Y. & Zhao, C. X. Particle-based synthetic antigen-presenting cell techniques for T cell activation in adoptive T cell remedy. ACS Nano 18, 8571–8599 (2024).
Hu, T., Kumar, A. R. Ok., Luo, Y. & Tay, A. Automating CAR-T transfection with micro and nano-technologies. Small Strategies 8, e2301300 (2024).
Sunshine, J. C. & Inexperienced, J. J. Nanoengineering approaches to the design of synthetic antigen-presenting cells. Nanomedicine 8, 1173–1189 (2013).
Dahotre, S. N., Romanov, A. M., Su, F. Y. & Kwong, G. A. Artificial antigen-presenting cells for adoptive T cell remedy. Adv. Ther. 4, 2100034 (2021).
Ben-Akiva, E. et al. Form issues: biodegradable anisotropic nanoparticle synthetic antigen presenting cells for most cancers immunotherapy. Acta Biomater. 160, 187–197 (2023).
Perica, Ok. et al. Nanoscale synthetic antigen presenting cells for T cell immunotherapy. Nanomedicine 10, 119–129 (2014).
Isser, A. et al. Nanoparticle-based modulation of CD4+ T cell effector and helper capabilities enhances adoptive immunotherapy. Nat. Commun. 13, 6086 (2022).
Ichikawa, J. et al. Speedy growth of extremely purposeful antigen-specific T cells from sufferers with melanoma by nanoscale synthetic antigen-presenting cells. Clin. Most cancers Res. 26, 3384–3396 (2020).
Lee, Ok. & Yu, Y. Janus nanoparticles for T cell activation: clustering ligands to reinforce stimulation. J. Mater. Chem. B 5, 4410–4415 (2017).
Matic, J., Deeg, J., Scheffold, A., Goldstein, I. & Spatz, J. P. High quality tuning and environment friendly T cell activation with stimulatory aCD3 nanoarrays. Nano Lett. 13, 5090–5097 (2013).
Guasch, J., Muth, C. A., Diemer, J., Riahinezhad, H. & Spatz, J. P. Integrin-assisted T-cell activation on nanostructured hydrogels. Nano Lett. 17, 6110–6116 (2017). This work proposes that the nanoscale association of anti-CD3 and integrin-binding ligands will be strategically engineered to modulate T cell activation.
Pinheiro, A. V., Han, D., Shih, W. M. & Yan, H. Challenges and alternatives for structural DNA nanotechnology. Nat. Nanotechnol. 6, 763–772 (2011).
Teixeira, A. I. et al. Spatial regulation of T-cell signaling by programmed death-ligand 1 on wireframe DNA origami flat sheets. ACS Nano 15, 3441–3452 (2021).
Hellmeier, J. et al. DNA origami show the distinctive stimulatory energy of single pMHCs as T-cell antigens. Biophys. J. 120, 330a (2021).
Cheung, A. S., Zhang, D. Ok. Y., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells allow ex vivo growth of major T cells. Nat. Biotechnol. 36, 160–169 (2018).
Fadel, T. R. et al. A carbon nanotube-polymer composite for T-cell remedy. Nat. Nanotechnol. 9, 639–647 (2014).
Jie, J., Mao, D., Cao, J., Feng, P. & Yang, P. Custom-made multifunctional peptide hydrogel scaffolds for CAR-T-cell fast proliferation and stable tumor immunotherapy. ACS Appl. Mater. Interfaces 14, 37514–37527 (2022).
Lambert, L. H. et al. Bettering T cell growth with a mushy contact. Nano Lett. 17, 821–826 (2017).
Mandal, S. et al. Polymer-based artificial dendritic cells for tailoring strong and multifunctional T cell responses. ACS Chem. Biol. 10, 485–492 (2015).
Aramesh, M. et al. Nanoconfinement of microvilli alters gene expression and boosts T cell activation. Proc. Natl Acad. Sci. USA 118, e2107535118 (2021).
Bhingardive, V. et al. Antibody-functionalized nanowires: a tuner for the activation of T cells. Nano Lett. 21, 4241–4248 (2021).
Esmaeili, F. et al. Spiky gold nanoparticles, a nanoscale method to enhanced ex vivo T-cell activation. ACS Nano 18, 21554–21564 (2024).
Lei, Ok., Kurum, A. & Tang, L. Mechanical immunoengineering of T cells for therapeutic functions. Acc. Chem. Res. 53, 2777–2790 (2020).
Perica, Ok. et al. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor exercise. ACS Nano 8, 2252–2260 (2014).
Liu, Z. et al. Nanoscale optomechanical actuators for controlling mechanotransduction in residing cells. Nat. Strategies 13, 143–146 (2016).
Zheng, Y. et al. Optoregulated drive software to mobile receptors utilizing molecular motors. Nat. Commun. 12, 3580 (2021).
Fu, D. et al. Mechanically optimize T cells activation by spiky nanomotors. Entrance. Bioeng. Biotechnol. 10, 844091 (2022).
Chada, N. C. & Wilson, J. T. Bounce-starting chimeric antigen receptor-T cells to go the additional mile with nanotechnology. Curr. Opin. Biotechnol. 89, 103179 (2024).
Belling, J. N. et al. Acoustofluidic sonoporation for gene supply to human hematopoietic stem and progenitor cells. Proc. Natl Acad. Sci. USA 117, 10976–10982 (2020).
Sytsma, B. J. et al. Scalable intracellular supply through microfluidic vortex shedding enhances the perform of chimeric antigen receptor T-cells. Sci. Rep. 15, 5749 (2025).
Aramesh, M. et al. Enhanced mobile uptake by way of nanotopography-induced macropinocytosis. Adv. Funct. Mater. 34, 2400487 (2024).
Pan, H. et al. Glycometabolic bioorthogonal chemistry-guided viral transduction for strong human T cell engineering. Adv. Funct. Mater. 29, 1807528 (2019).
Chen, Y. et al. Environment friendly non-viral CAR-T cell era through silicon-nanotube-mediated transfection. Mater. Immediately 63, 8–17 (2023).
Shokouhi, A. R. et al. Engineering environment friendly CAR-T cells through electroactive nanoinjection. Adv. Mat. 35, e2304122 (2023).
Tay, A. & Melosh, N. Mechanical stimulation after centrifuge-free nano-electroporative transfection is environment friendly and maintains long-term T cell functionalities. Small 17, 2103198 (2021).
Xiong, R. et al. Quick spatial-selective supply into stay cells. J. Management. Launch 266, 198–204 (2017).
Pinto, I. S., Cordeiro, R. A. & Faneca, H. Polymer- and lipid-based gene supply know-how for CAR T cell remedy. J. Management. Launch 353, 196–215 (2023).
Selby, L. I., Cortez-Jugo, C. M., Such, G. Ok. & Johnston, A. P. R. Nanoescapology: progress towards understanding the endosomal escape of polymeric nanoparticles. WIREs Nanomed. Nanobiotechnol. 9, e1452 (2017).
Olden, B. R., Cheng, Y., Yu, J. L. & Pun, S. H. Cationic polymers for non-viral gene supply to human T cells. J. Management. Launch 282, 140–147 (2018).
Prazeres, P. H. D. M. et al. Supply of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells. Int. J. Nanomed. 18, 5891–5904 (2023).
Billingsley, M. M. et al. Ionizable lipid nanoparticle-mediated mRNA supply for human CAR T cell engineering. Nano Lett. 20, 1578–1589 (2020).
Padilla, M. S. et al. Branched endosomal disruptor (BEND) lipids mediate supply of mRNA and CRISPR-Cas9 ribonucleoprotein complicated for hepatic gene modifying and T cell engineering. Nat. Commun. 16, 996 (2025).
Metzloff, A. E. et al. Antigen presenting cell mimetic lipid nanoparticles for fast mRNA CAR T cell most cancers immunotherapy. Adv. Mater. 36, 2313226 (2024). This publication presents lipid nanoparticles conjugated with anti-CD3 and anti-CD28, and encapsulating CAR mRNA, enabling activation and transfection of major human T cells in a single step.
Billingsley, M. M. et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533–542 (2022).
Yee Mon, Ok. J. et al. Functionalized nanowires for miRNA-mediated therapeutic programming of naïve T cells. Nat. Nanotech. 19, 1190–1202 (2024).
Hamilton, A. G. et al. Ionizable lipid nanoparticles with built-in immune checkpoint inhibition for mRNA CAR T cell engineering. Adv. Healthc. Mater. 12, 2301515 (2023).
Chamberlain, C. A. et al. Extremely environment friendly PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell remedy. Mol. Ther. Oncolytics 24, 417–428 (2022).
Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T cells and T-cell therapies for most cancers: a translational science overview. JAMA 22, 1924–1935 (2024).
Wang, L. et al. The dilemmas and potential options for CAR-T cell remedy software in stable tumors. Most cancers Lett. 591, 216871 (2024).
Zhang, A. Q. et al. Common redirection of CAR T cells in opposition to stable tumours through membrane-inserted ligands for the CAR. Nat. Biomed. Eng. 7, 1113–1128 (2023).
Reinhard, Ok. et al. An RNA vaccine drives growth and efficacy of claudin-CAR-T cells in opposition to stable tumors. Science 367, 446–453 (2020).
Yoon, J., Fagan, E., Jeong, M. & Park, J.-H. In situ tumor-infiltrating lymphocyte remedy by native supply of an mRNA encoding membrane-anchored anti-CD3 single-chain variable fragment. ACS Nano 18, 32401–32420 (2024). This work explores the usage of mRNA-loaded lipid nanoparticles in tumours, enabling the in vivo engineering of TAMs and tumour cells to precise anti-CD3 and thereby promote in situ engagement of TILs.
Stephan, M. T., Moon, J. J., Um, S. H., Bersthteyn, A. & Irvine, D. J. Therapeutic cell engineering with surface-conjugated artificial nanoparticles. Nat. Med. 16, 1035–1041 (2010).
Tang, L. et al. Enhancing T cell remedy by way of TCR-signaling-responsive nanoparticle drug supply. Nat. Biotechnol. 36, 707–716 (2018).
Luo, Y. et al. IL-12 nanochaperone-engineered CAR T cell for strong tumor-immunotherapy. Biomaterials 281, 121341 (2022).
Liu, Y. et al. Cytokine conjugation to reinforce T cell remedy. Proc. Natl Acad. Sci. USA 120, e2213222120 (2023).
Zheng, Y. et al. In vivo focusing on of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J. Management. Launch 172, 426–435 (2013).
Weiss, L. et al. Direct in vivo activation of T cells with nanosized immunofilaments inhibits tumor development and metastasis. ACS Nano 17, 12101–12117 (2023).
Solar, Y. et al. DNA origami–primarily based synthetic antigen-presenting cells for adoptive T cell remedy. Sci. Adv. 8, eadd1106 (2022).
Meyer, R. A. et al. Biodegradable nanoellipsoidal synthetic antigen presenting cells for antigen particular T-cell activation. Small 11, 1519 (2015).
Li, X. et al. Enhancing adoptive cell remedy by T cell loading of SHP2 inhibitor nanocrystals earlier than infusion. ACS Nano 16, 10918–10930 (2022).
Stephan, M. T., Stephan, S. B., Bak, P., Chen, J. & Irvine, D. J. Synapse-directed supply of immunomodulators utilizing T-cell-conjugated nanoparticles. Biomaterials 33, 5776–5787 (2012).
Siriwon, N. et al. CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Most cancers Immunol. Res. 6, 812–824 (2018).
Chen, Z. et al. Nanoengineered CAR-T biohybrids for stable tumor immunotherapy with microenvironment photothermal-remodeling technique. Small 17, 2007494 (2021).
Zhao, Z. et al. A collagenase nanogel backpack improves CAR-T cell remedy outcomes in pancreatic most cancers. Nat. Nanotechnol. https://doi.org/10.1038/s41565-025-01924-1 (2025).
Nie, W. et al. Magnetic nanoclusters armed with responsive PD-1 antibody synergistically improved adoptive T-cell remedy for stable tumors. ACS Nano 13, 1469–1478 (2019).
Schmid, D. et al. T cell-targeting nanoparticles focus supply of immunotherapy to enhance antitumor immunity. Nat. Commun. 8, 1747 (2017).
Zhang, F. et al. Nanoparticles that reshape the tumor milieu create a therapeutic window for efficient T-cell remedy in stable malignancies. Most cancers Res. 78, 3718–3730 (2018).
Chen, X. et al. Non-invasive activation of intratumoural gene modifying for improved adoptive T-cell remedy in stable tumours. Nat. Nanotechnol. 18, 933–944 (2023). This text presents a gentle heat-activated Cas9-based nanodevice that concurrently disrupts immunosuppression within the tumour microenvironment and the apoptotic resistance of tumour cells, enhancing the infiltration and efficacy of TILs and CAR T cells.
Zhu, T. et al. Inhalable nanovesicles loaded with a STING agonist improve CAR-T cell exercise in opposition to stable tumors within the lung. Nat. Commun. 16, 262 (2025).
An, J., Guo, R., Liu, M., Hu, H. & Zhang, H. Multi-modal Ca2+ nanogenerator through reversing T cell exhaustion for enhanced chemo-immunotherapy. J. Management. Launch 372, 715–727 (2024).
Miller, I. C. et al. Enhanced intratumoural exercise of CAR T cells engineered to supply immunomodulators underneath photothermal management. Nat. Biomed. Eng. 5, 1348–1359 (2021).
Nguyen, N. T. et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced security. Nat. Nanotechnol. 16, 1424–1434 (2021).
Pfister, F. et al. Loading of CAR-T cells with magnetic nanoparticles for managed focusing on suppresses inflammatory cytokine launch and switches tumor cell loss of life mechanism. MedComm 6, e70039 (2025).
Gong, N. et al. In situ PEGylation of CAR T cells alleviates cytokine launch syndrome and neurotoxicity. Nat. Mater. 22, 1571–1580 (2023).
Brief, L., Holt, R. A., Cullis, P. R. & Evgin, L. Direct in vivo CAR T cell engineering. Traits Pharmacol. Sci. 45, 406–418 (2024).
Smith, T. T. et al. In situ programming of leukaemia-specific T cells utilizing artificial DNA nanocarriers. Nat. Nanotechnol. 12, 813–820 (2017).
Zhu, C. et al. Injectable supramolecular hydrogels for in situ programming of CAR-T cells towards stable tumor immunotherapy. Adv. Mater. 36, 2310078 (2024).
Zhou, J. E. et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J. Management. Launch 350, 298–307 (2022).
Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S. & Stephan, M. T. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 6080 (2020). This research explores mRNA-loaded polymer nanocarriers that programme host T cells to transiently specific tumour-specific CARs immediately in vivo.
Billingsley, M. M. et al. In vivo mRNA CAR T cell engineering through focused ionizable lipid nanoparticles with extrahepatic tropism. Small 20, 2304378 (2024).
Álvarez-Benedicto, E. et al. Spleen SORT LNP generated in situ CAR T cells lengthen survival in a mouse mannequin of lymphoreplete B cell lymphoma. Angew. Chem. Int. Ed. 62, e202310395 (2023).
Zhao, G., Zhang, Y., Xu, C. F. & Wang, J. In vivo manufacturing of CAR-T cells utilizing virus-mimetic fusogenic nanovesicles. Sci. Bull. 69, 354–366 (2024).
Hamilton, E. et al. 801PRIMETM IL-15 (RPTR-147): preliminary scientific outcomes and biomarker evaluation from a first-in-human Section 1 research of IL-15 loaded peripherally-derived autologous T cell remedy in stable tumor sufferers. J. Immunother. Most cancers 8, A479–A480 (2020).
Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127–132 (2020).
Seif, M. et al. CAR T cells focusing on Aspergillus fumigatus are efficient at treating invasive pulmonary aspergillosis in preclinical fashions. Sci. Transl. Med. 14, eabh1209 (2022).
Mackensen, A. et al. Anti-CD19 CAR T cell remedy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022).
Lidar, M. et al. CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann. Rheum. Dis. 84, 370–372 (2024).
Mohammadi, V. et al. Chimeric antigen receptor (CAR)-based cell remedy for sort 1 diabetes mellitus (T1DM); present progress and future approaches. Stem. Cell. Rev. Rep. 20, 585–600 (2024).
Rurik, J. G. et al. CAR T cells produced in vivo to deal with cardiac harm. Science 375, 91–96 (2022).
Qasim, W. et al. Molecular remission of toddler B-ALL after infusion of common TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).
Schaible, P., Bethge, W., Lengerke, C. & Haraszti, R. A. RNA therapeutics for bettering CAR T-cell security and efficacy. Most cancers Res. 83, 354–362 (2023).
Themeli, M. et al. Era of tumor-targeted human T lymphocytes from induced pluripotent stem cells for most cancers remedy. Nat. Biotechnol. 31, 928–933 (2013).
Jing, R. et al. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor exercise. Cell Stem Cell 29, 1181–1196.E6 (2022).
Makkouk, A. et al. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 show strong antitumor efficacy in opposition to hepatocellular carcinoma. J. Immunother. Most cancers 9, e003441 (2021).
Liu, E. et al. Use of CAR-Transduced pure killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
Hudson, D., Fernandes, R. A., Basham, M., Ogg, G. & Koohy, H. Can we predict T cell specificity with digital biology and machine studying? Nat. Rev. Immunol. 23, 511–521 (2023). This angle article explores how integrating digital biology with machine studying can improve the prediction of TCR–antigen specificity, deepening our understanding of antigen immunogenicity and informing the event of CAR T and TIL therapies.
Zhang, D. Ok. Y. et al. Enhancing CAR-T cell performance in a patient-specific method. Nat. Commun. 14, 506 (2023).
Daniels, Ok. G. et al. Decoding CAR T cell phenotype utilizing combinatorial signaling motif libraries and machine studying. Science 378, 1194–1200 (2022).
Bogatu, A. et al. Meta-analysis knowledgeable machine studying: Supporting cytokine storm detection throughout CAR-T cell Remedy. J. Biomed. Inform. 142, 104367 (2023).
Arabi, F., Mansouri, V. & Ahmadbeigi, N. Gene remedy scientific trials, the place will we go? An summary. Biomed. Pharmacother. 153, 113324 (2022).
Moradi, V., Omidkhoda, A. & Ahmadbeigi, N. The paths and challenges of ‘off-the-shelf’ CAR-T cell remedy: an summary of scientific trials. Biomed. Pharmacother. 169, 115888 (2023).
Pfeiffer, A. et al. In vivo era of human CD 19‐ CAR T cells ends in B‐cell depletion and indicators of cytokine launch syndrome. EMBO Mol. Med. 10, e9158 (2018).
Agarwal, S., Weidner, T., Thalheimer, F. B. & Buchholz, C. J. In vivo generated human CAR T cells eradicate tumor cells. Oncoimmunology 8, e1671761 (2019).
Agarwal, S. et al. In vivo era of CAR T cells selectively in human CD4+ lymphocytes. Mol. Ther. 28, 1783–1794 (2020).
Frank, A. M. et al. Combining T-cell–particular activation and in vivo gene supply by way of CD3-targeted lentiviral vectors. Blood Adv. 4, 5702–5715 (2020).
Nicolai, C. J. et al. In vivo CAR T-cell era in nonhuman primates utilizing lentiviral vectors displaying a multidomain fusion ligand. Blood 144, 977–987 (2024).
Michels, Ok. R. et al. Preclinical proof of idea for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J. Immunother. Most cancers 11, e006292 (2023).
Huckaby, J. T. et al. Bispecific binder redirected lentiviral vector allows in vivo engineering of CAR-T cells. J. Immunother. Most cancers 9, e002737 (2021).
Nawaz, W. et al. AAV-mediated in vivo CAR gene remedy for focusing on human T-cell leukemia. Blood Most cancers J. 11, 119 (2021).
Jeffreys, N., Brockman, J. M., Zhai, Y., Ingber, D. E. & Mooney, D. J. Mechanical forces amplify TCR mechanotransduction in T cell activation and performance. Appl. Phys. Rev. 11, 011304 (2024).
Li, R., Ma, C., Cai, H. & Chen, W. The CAR T-cell mechanoimmunology at a look. Adv. Sci. 7, 2002628 (2020).
Chow, A., Perica, Ok., Klebanoff, C. A. & Wolchok, J. D. Scientific implications of T cell exhaustion for most cancers immunotherapy. Nat. Rev. Clin. Oncol. 19, 775–790 (2022).
Yin, X., He, L. & Guo, Z. T-cell exhaustion in CAR-T-cell remedy and techniques to beat it. Immunology 169, 400–411 (2023).
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering methods to beat the present roadblocks in CAR T cell remedy. Nat. Rev. Clin. Oncol. 17, 147–167 (2019).
Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity because of CAR T cells. Nat. Med. 24, 739–748 (2018).
Hughes, A. D., Teachey, D. T. & Diorio, C. Driving the storm: managing cytokine-related toxicities in CAR-T cell remedy. Semin. Immunopathol. 46, 1–19 (2024).